docetaxel anhydrous has been researched along with Papillomavirus Infections in 21 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 14 (66.67) | 24.3611 |
| 2020's | 7 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Fietkau, R; Frey, B; Gaipl, US; Gehre, S; Gostian, AO; Grottker, F; Hecht, M; Jost, T; Reichardt, CM; Rieckmann, T; Rückert, M; Sengedorj, A | 1 |
| Bouganim, N; Fuson, A; Joshi, AS; Khalife, S; Mascarella, MA; Ramanakumar, AV; Richardson, K; Sadeghi, N; Siegel, R; Taheri, R | 1 |
| Brizel, DM; Choudhury, KR; Das, S; Mowery, YM; Niedzwiecki, D; Rushing, CN; Vergalasova, I; Wong, TZ; Wu, Q; Yoo, DS | 1 |
| Botticelli, A; Cerbelli, B; Cirillo, A; Corsi, A; De Vincentiis, M; Di Gioia, C; Marchetti, P; Mezi, S; Polimeni, A; Pomati, G; Roberto, M; Tombolini, V; Valentini, V; Vullo, F | 1 |
| Abdeljaoued, S; Adotevi, O; Borg, C; Buecher, B; François, E; Kim, S; Meurisse, A; Spehner, L; Vernerey, D; Vienot, A | 1 |
| Borah, BJ; Chintakuntlawar, AV; Foote, RL; Garces, YI; Garcia, JJ; Graner, DE; Hallemeier, CL; Hinni, ML; Janus, JR; Kasperbauer, JL; Ma, DJ; May, JM; Miller, RC; Moore, EJ; Neben-Wittich, MA; Patel, SH; Price, DL; Price, KA; Visscher, SL; Waddle, MR | 1 |
| Blumenschein, GR; Garden, AS; Ginsberg, LE; Glisson, BS; Gold, KA; Haddad, RI; Hutcheson, K; Johnson, FM; Kies, MS; Lee, JJ; Lewis, J; Lin, HY; Massarelli, E; Myers, J; Papadimitrakopoulou, V; Pharaon, RR; Pickering, C; Rabinowits, G; Tishler, RB; William, WN; Williams, MD | 1 |
| Killock, D | 1 |
| Chintakuntlawar, AV; Foote, RL; Foster, NR; Garces, YI; Garcia, JJ; Ginos, B; Graner, DE; Hinni, ML; Janus, JR; Kasperbauer, JL; Ma, DJ; Miller, R; Moore, EJ; Neben-Wittich, M; Olsen, KD; Patel, SH; Price, DL; Price, KA; Shiraishi, S; Van Abel, KM; Waddle, M | 1 |
| Burke, MS; Ford, D; Kim, J; Loree, JT; Loree, TR; Popat, SR; Szymanowski, AR | 1 |
| Fury, MG; Haque, S; Heguy, A; Ho, AL; Katabi, N; Nwankwo, O; Pfister, DG; Sherman, E; Sima, C; Tsai, F; Xiao, H | 1 |
| Aderhold, C; Birk, R; Erben, P; Faber, A; Hofheinz, RD; Hörmann, K; Sauter, A; Schultz, JD; Sommer, JU; Stern-Straeter, J; Umbreit, C | 1 |
| Aderhold, C; Faber, A; Hoermann, K; Hofheinz, RD; Sauter, A; Schultz, JD; Sommer, JU; Stern-Sträter, J; Umbreit, C | 1 |
| Benzidane, B; Bonnetain, F; Borg, C; Bosset, JF; Cazorla, A; Delabrousse, E; Demarchi, M; Jary, M; Kaliski, A; Kim, S; Letondal, P; Mansi, L; Nguyen, T; Valmary-Degano, S | 1 |
| Bossi, P; Cortelazzi, B; Fallai, C; Gloghini, A; Granata, R; Guzzo, M; Licitra, L; Locati, L; Mariani, L; Miceli, R; Orlandi, E; Perrone, F; Pilotti, S; Scaramellini, G | 1 |
| Chung, CH; Fertig, EJ; Gillison, ML; Harari, PM; Harris, J; Jordan, RC; Kong, CS; Le, QT; Raben, D; Redmond, KP; Shenouda, G; Trotti, A; Wang, D; Zhang, Q | 1 |
| Arya, S; Bhattacharjee, A; D'Cruz, A; Dhumal, S; Joshi, A; Juvekar, S; Kane, S; Muddu, V; Noronha, V; Patil, VM; Prabhash, K | 1 |
| Bartůňková, J; Bieblová, J; Fučíková, J; Indrová, M; Mikyšková, R; Moserová, I; Reiniš, M; Šímová, J; Špíšek, R; Štěpánek, I; Truxová, I | 1 |
| Chen, G; Guan, R; Hu, S; Su, X; Wang, Y; Wu, J; Xu, W; Zhai, L | 1 |
| Chays, A; Maillard, S; Merol, JC; Nguyen, TD | 1 |
| Annino, DJ; Balboni, TA; Goguen, LA; Haddad, RI; Lorch, J; Norris, CM; Posner, MR; Sher, DJ; Thotakura, V; Tishler, RB | 1 |
7 trial(s) available for docetaxel anhydrous and Papillomavirus Infections
| Article | Year |
|---|---|
Early
Topics: Analysis of Variance; Antineoplastic Agents; Cisplatin; Docetaxel; Female; Fluorodeoxyglucose F18; Human papillomavirus 16; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Recurrence, Local; Oropharyngeal Neoplasms; Papillomavirus Infections; Positron Emission Tomography Computed Tomography; Proportional Hazards Models; Prospective Studies; Radiopharmaceuticals; Treatment Outcome; Tumor Burden | 2020 |
Anti-Telomerase CD4
Topics: Adaptive Immunity; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; CD4-Positive T-Lymphocytes; Cisplatin; Docetaxel; Female; Fluorouracil; Humans; Male; Middle Aged; Papillomavirus Infections; Prognosis; Prospective Studies; Telomerase; Th1 Cells | 2020 |
Costs of Definitive Chemoradiation, Surgery, and Adjuvant Radiation Versus De-Escalated Adjuvant Radiation per MC1273 in HPV+ Cancer of the Oropharynx.
Topics: Antineoplastic Agents; Chemoradiotherapy; Chemoradiotherapy, Adjuvant; Cost Savings; Costs and Cost Analysis; Docetaxel; Dose Fractionation, Radiation; Female; Follow-Up Studies; Hospitalization; Humans; Male; Middle Aged; Oropharyngeal Neoplasms; Papillomavirus Infections; Postoperative Period; Prospective Studies; Quality of Life; Radiotherapy, Adjuvant; Squamous Cell Carcinoma of Head and Neck; Surgical Procedures, Operative | 2021 |
Weekly paclitaxel, carboplatin, cetuximab, and cetuximab, docetaxel, cisplatin, and fluorouracil, followed by local therapy in previously untreated, locally advanced head and neck squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cetuximab; Cisplatin; Docetaxel; Female; Fluorouracil; Humans; Induction Chemotherapy; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Papillomaviridae; Papillomavirus Infections; Progression-Free Survival; Squamous Cell Carcinoma of Head and Neck | 2019 |
Phase II Evaluation of Aggressive Dose De-Escalation for Adjuvant Chemoradiotherapy in Human Papillomavirus-Associated Oropharynx Squamous Cell Carcinoma.
Topics: Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Chemoradiotherapy, Adjuvant; Combined Modality Therapy; Cyclin-Dependent Kinase Inhibitor p16; Deglutition; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Radiation; Female; Follow-Up Studies; Humans; Male; Middle Aged; Oropharyngeal Neoplasms; Papillomaviridae; Papillomavirus Infections; Postoperative Period; Prospective Studies; Quality of Life; Radiation Dosage; Self Report; Smoking; Treatment Outcome | 2019 |
A phase 1 study of everolimus plus docetaxel plus cisplatin as induction chemotherapy for patients with locally and/or regionally advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Everolimus; Female; Head and Neck Neoplasms; Humans; Induction Chemotherapy; Male; Maximum Tolerated Dose; Middle Aged; Mutation; Neoplasm Staging; Papillomavirus Infections; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Risk Assessment; Risk Factors; Signal Transduction; Sirolimus; Smoking; Taxoids; TOR Serine-Threonine Kinases; Treatment Outcome | 2013 |
p16 protein expression and human papillomavirus status as prognostic biomarkers of nonoropharyngeal head and neck squamous cell carcinoma.
Topics: Antibodies, Monoclonal, Humanized; Biomarkers, Tumor; Carcinoma, Squamous Cell; Cetuximab; Cisplatin; Cyclin-Dependent Kinase Inhibitor p16; Disease-Free Survival; Docetaxel; Dose Fractionation, Radiation; Gene Expression Regulation, Neoplastic; Head and Neck Neoplasms; Humans; Immunohistochemistry; Neoplasm Proteins; Papillomaviridae; Papillomavirus Infections; Prognosis; Smoking; Taxoids; Treatment Outcome | 2014 |
14 other study(ies) available for docetaxel anhydrous and Papillomavirus Infections
| Article | Year |
|---|---|
Radiotherapy combined with docetaxel alters the immune phenotype of HNSCC cells and results in increased surface expression of CD137 and release of HMGB1 of specifically HPV-positive tumor cells.
Topics: Carcinoma, Squamous Cell; Docetaxel; Head and Neck Neoplasms; HMGB1 Protein; Humans; Papillomavirus Infections; Phenotype; Squamous Cell Carcinoma of Head and Neck | 2023 |
Pathologic response to neoadjuvant chemotherapy in HPV-associated oropharynx cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Female; Humans; Neoadjuvant Therapy; Oropharyngeal Neoplasms; Papillomavirus Infections; Treatment Outcome | 2020 |
Induction chemotherapy in nonlaryngeal human papilloma virus-negative high-risk head and neck cancer: a real-world experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Induction Chemotherapy; Laryngeal Neoplasms; Male; Middle Aged; Papillomavirus Infections; Progression-Free Survival; Retrospective Studies; Squamous Cell Carcinoma of Head and Neck; Treatment Outcome | 2020 |
Towards risk-stratified induction regimens.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cetuximab; Cisplatin; Clinical Trials, Phase II as Topic; Docetaxel; Fluorouracil; Head and Neck Neoplasms; Humans; Paclitaxel; Papillomavirus Infections; Squamous Cell Carcinoma of Head and Neck; Survival Analysis; Treatment Outcome | 2019 |
Presurgical induction chemotherapy for squamous cell carcinoma of the tonsil.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Squamous Cell; Cisplatin; Cohort Studies; Docetaxel; Female; Humans; Induction Chemotherapy; Male; Middle Aged; Neck Dissection; Papillomavirus Infections; Preoperative Period; Retrospective Studies; Tonsillar Neoplasms | 2020 |
Chemotherapeutic alteration of VEGF, PDGF and PDGFRα/β expression under 5-FU vs. docetaxel in HPV-transformed squamous cell carcinoma compared to HPV-negative HNSCC in vitro.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Blotting, Western; Carcinoma, Squamous Cell; Cell Proliferation; Cell Transformation, Viral; Docetaxel; Enzyme-Linked Immunosorbent Assay; Fluorouracil; Head and Neck Neoplasms; Human papillomavirus 16; Humans; Immunoenzyme Techniques; In Vitro Techniques; Papillomavirus Infections; Platelet-Derived Growth Factor; Receptor, Platelet-Derived Growth Factor alpha; Receptor, Platelet-Derived Growth Factor beta; Taxoids; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A | 2013 |
Unexpected alteration of β-catenin and c-KIT expression by 5-FU and docetaxel in p16-positive squamous cell carcinoma compared to HPV-negative HNSCC cells in vitro.
Topics: Antimetabolites; Antineoplastic Agents; beta Catenin; Carcinoma, Squamous Cell; Cell Line, Tumor; Docetaxel; Enzyme-Linked Immunosorbent Assay; Fluorouracil; Head and Neck Neoplasms; Human papillomavirus 16; Humans; Immunohistochemistry; Papillomavirus Infections; Proto-Oncogene Proteins c-kit; Signal Transduction; Taxoids; Wnt Signaling Pathway | 2013 |
DCF (docetaxel, cisplatin and 5-fluorouracil) chemotherapy is a promising treatment for recurrent advanced squamous cell anal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Cisplatin; Disease-Free Survival; Docetaxel; Female; Fluorouracil; Human papillomavirus 16; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Squamous Cell; Papillomavirus Infections; Prospective Studies; Retrospective Studies; Taxoids; Treatment Outcome | 2013 |
Treatment-related outcome of oropharyngeal cancer patients differentiated by HPV dictated risk profile: a tertiary cancer centre series analysis.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Cyclin-Dependent Kinase Inhibitor p16; Disease-Free Survival; Docetaxel; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Staging; Oropharyngeal Neoplasms; Papillomaviridae; Papillomavirus Infections; Retrospective Studies; Taxoids; Tertiary Care Centers; Treatment Outcome | 2014 |
Neoadjuvant Chemotherapy in Technically Unresectable Oral Cancers: Does Human Papillomavirus Make a Difference?
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Cisplatin; Cohort Studies; Docetaxel; Female; Follow-Up Studies; Humans; Male; Middle Aged; Mouth Neoplasms; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Papillomaviridae; Papillomavirus Infections; Prognosis; Survival Rate; Taxoids; Young Adult | 2015 |
Dendritic cells pulsed with tumor cells killed by high hydrostatic pressure induce strong immune responses and display therapeutic effects both in murine TC-1 and TRAMP-C2 tumors when combined with docetaxel chemotherapy.
Topics: Animals; Antigens, Neoplasm; Antineoplastic Agents; Cancer Vaccines; Cell Line, Tumor; Cytotoxicity, Immunologic; Dendritic Cells; Docetaxel; Humans; Hydrostatic Pressure; Immune System; Immunotherapy; Interferon-gamma; Interleukin-12; Male; Mice; Mice, Inbred C57BL; Neoplasms, Experimental; Papillomavirus Infections; Prostatic Neoplasms; Spleen; Taxoids; Toll-Like Receptor 9 | 2016 |
Adjuvant effect of docetaxel on HPV16 L2E6E7 fusion protein vaccine in a mouse model.
Topics: Adjuvants, Immunologic; Animals; Cancer Vaccines; Capsid Proteins; Cell Line, Tumor; Cytotoxicity, Immunologic; Docetaxel; Female; Human papillomavirus 16; Humans; Immunity, Humoral; Mice; Mice, Inbred C57BL; Oncogene Proteins, Viral; Papillomavirus E7 Proteins; Papillomavirus Infections; Recombinant Fusion Proteins; Repressor Proteins; Taxoids; Tumor Burden; Uterine Cervical Neoplasms; Vaccines, Synthetic | 2016 |
[In reference to the article: "Neck dissection following chemoradiation for node positive head and neck carcinomas" by Thariat et al. Cancer Radiother 2009;13:758-770].
Topics: Alphapapillomavirus; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials as Topic; Combined Modality Therapy; Docetaxel; Drug Administration Schedule; Fluorouracil; Head and Neck Neoplasms; Humans; Lymphatic Metastasis; Neck Dissection; Neoadjuvant Therapy; Neoplasm Staging; Papillomavirus Infections; Radiotherapy, Adjuvant; Taxoids; Treatment Outcome | 2010 |
Treatment of oropharyngeal squamous cell carcinoma with IMRT: patterns of failure after concurrent chemoradiotherapy and sequential therapy.
Topics: Aged; Albumin-Bound Paclitaxel; Albumins; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Female; Fluorouracil; Human papillomavirus 16; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Oropharyngeal Neoplasms; Paclitaxel; Panitumumab; Papillomavirus Infections; Proportional Hazards Models; Radiation Tolerance; Radiotherapy, Intensity-Modulated; Retrospective Studies; Taxoids; Treatment Failure | 2012 |